{"markup":"\u003C?xml version=\u00221.0\u0022 encoding=\u0022UTF-8\u0022 ?\u003E\n    \u003Chtml version=\u0022HTML+RDFa+MathML 1.1\u0022\n    xmlns:content=\u0022http:\/\/purl.org\/rss\/1.0\/modules\/content\/\u0022\n    xmlns:dc=\u0022http:\/\/purl.org\/dc\/terms\/\u0022\n    xmlns:foaf=\u0022http:\/\/xmlns.com\/foaf\/0.1\/\u0022\n    xmlns:og=\u0022http:\/\/ogp.me\/ns#\u0022\n    xmlns:rdfs=\u0022http:\/\/www.w3.org\/2000\/01\/rdf-schema#\u0022\n    xmlns:sioc=\u0022http:\/\/rdfs.org\/sioc\/ns#\u0022\n    xmlns:sioct=\u0022http:\/\/rdfs.org\/sioc\/types#\u0022\n    xmlns:skos=\u0022http:\/\/www.w3.org\/2004\/02\/skos\/core#\u0022\n    xmlns:xsd=\u0022http:\/\/www.w3.org\/2001\/XMLSchema#\u0022\n    xmlns:mml=\u0022http:\/\/www.w3.org\/1998\/Math\/MathML\u0022\u003E\n  \u003Chead\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/sites\/default\/files\/js\/js_itu2PgFdrjV-docKmLK8Jn5oXe_05RgvQh73eOhI_mE.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_at_symbol.js?nzljm1\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_article_reference_popup.js?nzljm1\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/sites\/default\/files\/js\/js_I8yX6RYPZb7AtMcDUA3QKDZqVkvEn35ED11_1i7vVpc.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\n(function(i,s,o,g,r,a,m){i[\u0022GoogleAnalyticsObject\u0022]=r;i[r]=i[r]||function(){(i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)})(window,document,\u0022script\u0022,\u0022\/\/www.google-analytics.com\/analytics.js\u0022,\u0022ga\u0022);ga(\u0022create\u0022, \u0022UA-15605596-27\u0022, {\u0022cookieDomain\u0022:\u0022auto\u0022});ga(\u0022set\u0022, \u0022page\u0022, location.pathname + location.search + location.hash);ga(\u0022send\u0022, \u0022pageview\u0022);ga(\u0027create\u0027, \u0027UA-189672-26\u0027, \u0027auto\u0027, {\u0027name\u0027: \u0027hwTracker\u0027});\r\nga(\u0027hwTracker.send\u0027, \u0027pageview\u0027);\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\njQuery.extend(Drupal.settings, {\u0022basePath\u0022:\u0022\\\/\u0022,\u0022pathPrefix\u0022:\u0022\u0022,\u0022highwire\u0022:{\u0022markup\u0022:[{\u0022requested\u0022:\u0022full-text\u0022,\u0022variant\u0022:\u0022full-text\u0022,\u0022view\u0022:\u0022full\u0022,\u0022pisa\u0022:\u0022spmdc;15\\\/12\\\/26\u0022},{\u0022requested\u0022:\u0022long\u0022,\u0022variant\u0022:\u0022full-text\u0022,\u0022view\u0022:\u0022full\u0022,\u0022pisa\u0022:\u0022spmdc;15\\\/12\\\/26\u0022}],\u0022ac\u0022:{\u0022spmdc;15\\\/12\\\/26\u0022:{\u0022access\u0022:{\u0022reprint\u0022:true,\u0022full\u0022:true},\u0022pisa_id\u0022:\u0022spmdc;15\\\/12\\\/26\u0022,\u0022atom_uri\u0022:\u0022\u0022,\u0022jcode\u0022:\u0022spmdc\u0022}}},\u0022googleanalytics\u0022:{\u0022trackOutbound\u0022:1,\u0022trackMailto\u0022:1,\u0022trackDownload\u0022:1,\u0022trackDownloadExtensions\u0022:\u00227z|aac|arc|arj|asf|asx|avi|bin|csv|doc(x|m)?|dot(x|m)?|exe|flv|gif|gz|gzip|hqx|jar|jpe?g|js|mp(2|3|4|e?g)|mov(ie)?|msi|msp|pdf|phps|png|ppt(x|m)?|pot(x|m)?|pps(x|m)?|ppam|sld(x|m)?|thmx|qtm?|ra(m|r)?|sea|sit|tar|tgz|torrent|txt|wav|wma|wmv|wpd|xls(x|m|b)?|xlt(x|m)|xlam|xml|z|zip\u0022,\u0022trackUrlFragments\u0022:1},\u0022ajaxPageState\u0022:{\u0022js\u0022:{\u0022sites\\\/all\\\/libraries\\\/cluetip\\\/jquery.cluetip.js\u0022:1,\u0022sites\\\/all\\\/libraries\\\/cluetip\\\/lib\\\/jquery.hoverIntent.js\u0022:1,\u0022sites\\\/all\\\/libraries\\\/cluetip\\\/lib\\\/jquery.bgiframe.min.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/plugins\\\/highwire_markup_process\\\/js\\\/highwire_at_symbol.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/plugins\\\/highwire_markup_process\\\/js\\\/highwire_article_reference_popup.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/contrib\\\/google_analytics\\\/googleanalytics.js\u0022:1,\u00220\u0022:1}}});\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Clink type=\u0022text\/css\u0022 rel=\u0022stylesheet\u0022 href=\u0022\/\/d282kpwvnogo5m.cloudfront.net\/sites\/default\/files\/advagg_css\/css__ce2QY63WIanKyr8eSq7eavr1XQRRmFD6ZSmwpyJi8lM__zXwFqpqmxrZOXXcd_TpBQpjuELbmIP9wBR5UuTDWAO4__YJWWMMdfCJuAFm5cUEp88OsodhO3ZA-2lzRfoBsSlk4.css\u0022 media=\u0022all\u0022 \/\u003E\n\u003Clink rel=\u0027stylesheet\u0027 type=\u0027text\/css\u0027 href=\u0027\/sites\/all\/modules\/contrib\/panels\/plugins\/layouts\/onecol\/onecol.css\u0027 \/\u003E\u003C\/head\u003E\u003Cbody\u003E\u003Cdiv class=\u0022panels-ajax-tab-panel panels-ajax-tab-panel-sageoa-tab-art\u0022\u003E\u003Cdiv class=\u0022panel-display panel-1col clearfix\u0022 \u003E\n  \u003Cdiv class=\u0022panel-panel panel-col\u0022\u003E\n    \u003Cdiv\u003E\u003Cdiv class=\u0022panel-pane pane-highwire-markup\u0022 \u003E\n  \n      \n  \n  \u003Cdiv class=\u0022pane-content\u0022\u003E\n    \u003Cdiv class=\u0022highwire-markup\u0022\u003E\u003Cdiv xmlns=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022 id=\u0022content-block-markup\u0022 xmlns:xhtml=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022\u003E\u003Cdiv class=\u0022article fulltext-view \u0022\u003E\u003Cspan class=\u0022highwire-journal-article-marker-start\u0022\u003E\u003C\/span\u003E\u003Cdiv class=\u0022section abstract\u0022 id=\u0022abstract-1\u0022\u003E\u003Ch2\u003ESummary\u003C\/h2\u003E\u003Cp id=\u0022p-1\u0022\u003EThis article provides updates in the fields of device therapy for ventricular arrhythmias\u2014including risk stratification regarding patient selection for implantable cardioverter defibrillators, the optimal programming for implantable cardioverter defibrillators to reduce inappropriate shocks, the impact of sports participation on patients with implantable cardioverter defibrillators, and the future of resynchronization therapy.\u003C\/p\u003E\u003C\/div\u003E\u003Cul class=\u0022kwd-group\u0022\u003E\u003Cli class=\u0022kwd\u0022\u003Esudden cardiac death\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Emyocardial infarction\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Eventricular tachycardia\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Erisk stratification\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Eimplantable cardioverter defibrillator\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003EICD programming\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Eantitachycardia pacing\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Esports\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Ecardiac resynchronization therapy\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Einterventional techniques \u0026amp; devices\u003C\/li\u003E\u003C\/ul\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-1\u0022\u003E\u003Cp id=\u0022p-2\u0022\u003EDuring this state-of-the-art session, experts discussed aspects of managing patients with ventricular arrhythmias. David S. Cannom, MD, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, California, USA, opened the session with an update on risk stratification for sudden cardiac death.\u003C\/p\u003E\u003Cp id=\u0022p-3\u0022\u003EIt was determined 30 years ago that a left ventricular ejection fraction (LVEF) \u0026lt;\u200540% was indicative of increased mortality risk. However, as one 2005 study showed, not much progress has been made; once LVEF is elevated \u0026gt;\u200545%, it does not add much new information to help assess cardiovascular risk in heart failure patients. As a sole risk stratification tool, it misses the majority of sudden cardiac death cases that occur in individuals with preserved or only moderately reduced LVEF. According to Dr Cannom, even among patients with severely reduced LVEF, only a portion will benefit from the implantable cardioverter defibrillator (ICD), since some still have a low individual risk.\u003C\/p\u003E\u003Cp id=\u0022p-4\u0022\u003EDaubert and colleagues used data from the MADIT II electrophysiology study to show that inducibility predicted an increased likelihood of ventricular tachycardia (VT) and that noninducible patients had more risk factors as well as higher VT events and mortality rates [Daubert JP et al. \u003Cem\u003EJ Am Coll Cardiol\u003C\/em\u003E. 2006]. Unfortunately, electrophysiology studies have poor reproducibility.\u003C\/p\u003E\u003Cp id=\u0022p-5\u0022\u003EThere have been advances, however. One study showed that myocardial scarring, detected by magnetic resonance imaging, is useful in stratifying risk when selecting patients for an ICD [Klem I et al. \u003Cem\u003EJ Am Coll Cardiol\u003C\/em\u003E. 2012]. In patients with LVEF \u0026gt;\u200530%, significant scarring (\u0026gt;\u20055% left ventricular [LV]) identifies a high-risk cohort similar in risk to those with LVEF \u2264\u200530% (\u003Cem\u003EP\u003C\/em\u003E\u2005=\u2005.56). Conversely, in patients with LVEF \u2264\u200530%, minimal or no scarring identifies a low-risk cohort similar to those with LVEF \u0026gt;\u200530% (\u003Cem\u003EP\u2005\u003C\/em\u003E=\u2005.71; \u003Ca id=\u0022xref-fig-1-1\u0022 class=\u0022xref-fig\u0022 href=\u0022#F1\u0022\u003EFigure 1\u003C\/a\u003E).\u003C\/p\u003E\u003Cdiv id=\u0022F1\u0022 class=\u0022fig pos-float  odd\u0022\u003E\u003Cdiv class=\u0022highwire-figure\u0022\u003E\u003Cdiv class=\u0022fig-inline-img-wrapper\u0022\u003E\u003Cdiv class=\u0022fig-inline-img\u0022\u003E\u003Ca href=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/content\/spmdc\/15\/12\/26\/F1.large.jpg?width=800\u0026amp;height=600\u0026amp;carousel=1\u0022 title=\u0022Myocardial Scarring as Predictor of Death or ICD DischargeThe percentage of patients with the primary endpoint of death or appropriate ICD discharge is shown according to different levels of left ventricular ejection fraction (Panel a) and scar size (Panel b). For ejection fraction, the trendline (red line) shows a positive slope over the entire range, indicating that event rate monotonically increases with decreasing LVEF. In contrast, a marked step-up in event rate is noted for scar size greater than 5% of left ventricular mass, which however does not rise further with increasing scar size.Reprinted from J Am Coll Cardiol, Vol. 60, Klem I et al., Assessment of Myocardial Scarring Improves Risk Stratification in Patients Evaluated for Cardiac Defibrillator Implantation, Pages No. 408-420, Copyright (2012), with permission from American College of Cardiology Foundation.\u0022 class=\u0022fragment-images colorbox-load\u0022 rel=\u0022gallery-fragment-images-1245973970\u0022 data-figure-caption=\u0022\u0026amp;lt;div xmlns=\u0026amp;quot;http:\/\/www.w3.org\/1999\/xhtml\u0026amp;quot;\u0026amp;gt;Myocardial Scarring as Predictor of Death or ICD DischargeThe percentage of patients with the primary endpoint of death or appropriate ICD discharge is shown according to different levels of left ventricular ejection fraction (\u0026amp;lt;strong\u0026amp;gt;Panel a)\u0026amp;lt;\/strong\u0026amp;gt; and scar size (\u0026amp;lt;strong\u0026amp;gt;Panel b\u0026amp;lt;\/strong\u0026amp;gt;). For ejection fraction, the trendline (red line) shows a positive slope over the entire range, indicating that event rate monotonically increases with decreasing LVEF. In contrast, a marked step-up in event rate is noted for scar size greater than 5% of left ventricular mass, which however does not rise further with increasing scar size.Reprinted from \u0026amp;lt;em\u0026amp;gt;J Am Coll Cardiol\u0026amp;lt;\/em\u0026amp;gt;, Vol. 60, Klem I et al., Assessment of Myocardial Scarring Improves Risk Stratification in Patients Evaluated for Cardiac Defibrillator Implantation, Pages No. 408-420, Copyright (2012), with permission from American College of Cardiology Foundation.\u0026amp;lt;\/div\u0026amp;gt;\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003E\u003Cimg class=\u0022fragment-image\u0022 alt=\u0022Figure 1.\u0022 src=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/content\/spmdc\/15\/12\/26\/F1.medium.gif\u0022\/\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cul class=\u0022highwire-figure-links inline\u0022\u003E\u003Cli class=\u00220 first\u0022\u003E\u003Ca href=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/content\/spmdc\/15\/12\/26\/F1.large.jpg?download=true\u0022 class=\u0022highwire-figure-link highwire-figure-link-download\u0022 title=\u0022Download Figure 1.\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload figure\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u00221\u0022\u003E\u003Ca href=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/content\/spmdc\/15\/12\/26\/F1.large.jpg\u0022 class=\u0022highwire-figure-link highwire-figure-link-newtab\u0022 target=\u0022_blank\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EOpen in new tab\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u00222 last\u0022\u003E\u003Ca href=\u0022\/highwire\/powerpoint\/16712\u0022 class=\u0022highwire-figure-link highwire-figure-link-ppt\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload powerpoint\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003Cdiv class=\u0022fig-caption\u0022 xmlns:xhtml=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022\u003E\u003Cspan class=\u0022fig-label\u0022\u003EFigure 1.\u003C\/span\u003E \u003Cp id=\u0022p-6\u0022 class=\u0022first-child\u0022\u003EMyocardial Scarring as Predictor of Death or ICD Discharge\u003C\/p\u003E\u003Cp id=\u0022p-7\u0022\u003EThe percentage of patients with the primary endpoint of death or appropriate ICD discharge is shown according to different levels of left ventricular ejection fraction (\u003Cstrong\u003EPanel a)\u003C\/strong\u003E and scar size (\u003Cstrong\u003EPanel b\u003C\/strong\u003E). For ejection fraction, the trendline (red line) shows a positive slope over the entire range, indicating that event rate monotonically increases with decreasing LVEF. In contrast, a marked step-up in event rate is noted for scar size greater than 5% of left ventricular mass, which however does not rise further with increasing scar size.\u003C\/p\u003E\u003Cp id=\u0022p-8\u0022\u003EReprinted from \u003Cem\u003EJ Am Coll Cardiol\u003C\/em\u003E, Vol. 60, Klem I et al., Assessment of Myocardial Scarring Improves Risk Stratification in Patients Evaluated for Cardiac Defibrillator Implantation, Pages No. 408-420, Copyright (2012), with permission from American College of Cardiology Foundation.\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-2\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EOptimal ICD Programming\u003C\/h2\u003E\u003Cp id=\u0022p-9\u0022\u003EThe most important objective of optimal ICD programming is the detection and treatment of life-threatening VT\/ventricular fibrillation (VF). The reduction of unnecessary shocks is an important secondary objective. Charles D. Swerdlow, MD, Cedars-Sinai Medical Center, Los Angeles, California, USA, provided a preview of a few of the recommendations from the forthcoming (fall 2015) expert consensus statement on ICD programming and testing, led by several global heart rhythm societies.\u003C\/p\u003E\u003Cp id=\u0022p-10\u0022\u003ETwo draft recommendations for supraventricular tachycardia (SVT)\u2013VT discrimination algorithms are expected. The primary recommendation is to program SVT-VT discrimination with recommended rates \u2264\u2005200 to 230 beats per minute (bpm), unless contraindicated (class I: programming should be done). The secondary recommendation, which is for subcutaneous ICD, calls for programming 2 tachycardia zones with SVT-VT discrimination \u2264\u2005200 to 230 bpm (class IIA: programming is reasonable). Dr Swerdlow believes that the most useful individual discriminator is the ventricular electrogram morphology recorded from the shock (or far-field channel).\u003C\/p\u003E\u003Cp id=\u0022p-11\u0022\u003EOptimal ICD programming to reduce unnecessary shocks should minimize inappropriate detection of SVT as VT, oversensing of rapid intervals as VT\/VF intervals, and unnecessary therapy for slow or self-terminating VT. It should also terminate life-threatening VT with programmed antitachycardia pacing (ATP) when possible and prevent proarrhythmia. To that end, the draft consensus includes recommendations that the following should be programmed: a lead failure alert based on oversensing, with or without abrupt impendence changes (class I); lead \u201cnoise\u201d algorithms that withhold shocks when the VT\/VF on the sensing channel is not confirmed on the far-field channel (class IIb: programming may be considered); and algorithms designed to reject T-wave over-sensing (class IIB). The consensus statement is also expected to include a recommendation to program ATP for all VT\/VF zones \u2264\u2005230 bpm in patients with structural heart disease and to program burst ATP in preference to ramp ATP (both class I).\u003C\/p\u003E\u003Cp id=\u0022p-12\u0022\u003EIn summary, the draft recommendations include longer duration (6-12 seconds or 30 intervals) and faster rates (185-200 bpm) for primary VT\/VF detection, SVT-VT discriminators with recommended values (\u2264\u2005200 to 230 bpm), the use of far-field electrogram morphology discriminators if available, and the use of ATP burst \u2264\u2005230 bpm in patients with structural disease.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-3\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EImpact of Sports Participation on Patients With ICDs\u003C\/h2\u003E\u003Cp id=\u0022p-13\u0022\u003ERachel J. Lampert, MD, Yale School of Medicine, New Haven, Connecticut, USA, reported that many athletes with ICDs can participate in sports and recommended that sports participation for these athletes should be an individualized decision.\u003C\/p\u003E\u003Cp id=\u0022p-14\u0022\u003EDr Lampert reported results from a prospective multinational registry in individuals with ICDs who were participating in organized or high-risk sports [Lampert R et al. \u003Cem\u003ECirculation\u003C\/em\u003E. 2015]. The most common diagnoses were long QT syndrome, hypertrophic cardiomyopathy, and arrhythmogenic right ventricular cardiomyopathy. There were no incidents of tachyarrhythmic death or externally resuscitated tachyarrhythmia during or after sports nor injury due to arrhythmia or shock during sports at \u2265\u20052 years (95% CI, 0% to 1.5%). Appropriate shocks were more common during physical activity, competition, and other activity than at rest (\u003Ca id=\u0022xref-table-wrap-1-1\u0022 class=\u0022xref-table\u0022 href=\u0022#T1\u0022\u003ETable 1\u003C\/a\u003E). Lead malfunction rates were similar to those reported in unselected populations.\u003C\/p\u003E\u003Cdiv id=\u0022T1\u0022 class=\u0022table pos-float\u0022\u003E\u003Cdiv class=\u0022table-inline\u0022\u003E\u003Cdiv class=\u0022callout\u0022\u003E\u003Cspan\u003EView this table:\u003C\/span\u003E\u003Cul class=\u0022callout-links\u0022\u003E\u003Cli class=\u00220 first\u0022\u003E\u003Ca href=\u0022\/\u0022 class=\u0022table-expand-inline\u0022 data-table-url=\u0022\/highwire\/markup\/16713\/expansion?postprocessors=highwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0026amp;table-expand-inline=1\u0022 html=\u00221\u0022 fragment=\u0022#\u0022 external=\u00221\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView inline\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u00221\u0022\u003E\u003Ca href=\u0022\/highwire\/markup\/16713\/expansion?width=1000\u0026amp;height=500\u0026amp;iframe=true\u0026amp;postprocessors=highwire_figures%2Chighwire_math%2Chighwire_inline_linked_media\u0022 class=\u0022colorbox colorbox-load table-expand-popup\u0022 rel=\u0022gallery-fragment-tables\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView popup\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u00222 last\u0022\u003E\u003Ca href=\u0022\/highwire\/powerpoint\/16713\u0022 class=\u0022highwire-figure-link highwire-figure-link-ppt\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload powerpoint\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022table-caption\u0022\u003E\u003Cspan class=\u0022table-label\u0022\u003ETable 1.\u003C\/span\u003E \u003Cp id=\u0022p-15\u0022 class=\u0022first-child\u0022\u003EShock Activity During Sports\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cp id=\u0022p-20\u0022\u003EDr Lampert noted several caveats to the data. There were few athletes participating in violent contact sports, such as football or hockey, and there were no players with subcutaneous ICDs. Dr Lampert recommended stress testing to evaluate individual risk, as well as optimum programming for preventing unnecessary shocks, monitoring, and possible use of \u03b2-blockers.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-4\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EFuture of Cardiac Resynchronization Therapy\u003C\/h2\u003E\u003Cp id=\u0022p-21\u0022\u003EThe rates for cardiac resynchronization therapy (CRT) nonresponse have remained stable at about 30% over the past 8 years [Gorcsan John III. \u003Cem\u003ECirculation\u003C\/em\u003E. 2011]. The nonresponse rate, however, is dependent on the definition\/measurement of the end point, as well as time. Kenneth A. Ellenbogen, MD, Virginia Commonwealth University, Richmond, Virginia, USA, discussed individualizing and optimizing responses to CRT as ways to address this issue.\u003C\/p\u003E\u003Cp id=\u0022p-22\u0022\u003EIn one study, Q LV duration was associated with CRT response, indicating that Q LV measurement may be useful to guide LV lead placement [Gold MR et al. \u003Cem\u003EEur Heart J\u003C\/em\u003E. 2011]. The efficacy of CRT depends strongly on the patient-specific electrophysiologic substrate. Jia and colleagues suggested that electrocardiographic imaging, followed by the use of an endocardial (vs epicardial) LV pacing electrode, may be a better way of measuring this [Jia P et al. \u003Cem\u003EHeart Rhythm\u003C\/em\u003E. 2006].\u003C\/p\u003E\u003Cp id=\u0022p-23\u0022\u003EOne pacing approach employs ultrasound-mediated pacing that uses an ultrasound transmitter to bring acoustic waves from the chest wall to a receiver electrode in contact with the myocardium, which then converts the ultrasound energy to electrical energy adequate to pace.\u003C\/p\u003E\u003Cp id=\u0022p-24\u0022\u003EAnother approach is direct His bundle pacing, which produces synchronous ventricular depolarization and improved cardiac function relative to apical pacing. Long-term direct His bundle pacing results in a reduction of LV dimensions and improved cardiac function [Barba-Pichardo R et al. \u003Cem\u003EEuropace\u003C\/em\u003E. 2013].\u003C\/p\u003E\u003Cp id=\u0022p-25\u0022\u003EEndocardial LV pacing and direct His bundle pacing are both being assessed as potential alternatives to epicardial pacing.\u003C\/p\u003E\u003C\/div\u003E\u003Cul class=\u0022copyright-statement\u0022\u003E\u003Cli class=\u0022fn\u0022 id=\u0022copyright-statement-1\u0022\u003E\u00a9 2015 SAGE Publications\u003C\/li\u003E\u003C\/ul\u003E\u003Cspan class=\u0022highwire-journal-article-marker-end\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003Cspan id=\u0022related-urls\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003Ca href=\u0022http:\/\/mdc.sagepub.com\/content\/15\/12\/26.abstract\u0022 class=\u0022hw-link hw-link-article-abstract\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView Summary\u003C\/a\u003E\u003C\/div\u003E  \u003C\/div\u003E\n\n  \n  \u003C\/div\u003E\n\u003C\/div\u003E\n  \u003C\/div\u003E\n\u003C\/div\u003E\n\u003C\/div\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_figures.js?nzljm1\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_openurl.js?nzljm1\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_tables.js?nzljm1\u0022\u003E\u003C\/script\u003E\n\u003C\/body\u003E\u003C\/html\u003E"}